Derek Angus (BCHS ’92) named as associate vice chancellor for healthcare innovation.
This new role will complement his recent appointment as UPMC’s chief health care innovation officer, and foster strategic linkages between the two organizations. Dr. Angus will work to stimulate the fusion of multiple disciplines and skills, blending expertise in clinical care delivery with organization science, decision psychology, machine learning, Bayesian...
THE CONVERSATION - Respiratory scientist Douglas Reed, IDM and Pitt Med, examined studies that have shown how the virus has spread, including at a call center in South Korea, a restaurant in China, and a choir practice in Washington state. “The evidence strongly suggests that airborne transmission happens easily and is likely a significant driver of this pandemic. It must be taken seriously as people begin to venture back out into the world.”
CENTER FOR PUBLIC INTEGRITY - “It is a big leap forward,” said EPI's Wilbert van Panhuis, who is working to get access to the platform for a group of 600 researchers. “They are making major progress in this pandemic,” but much of the data was designed with federal government users in mind, not academic researchers or the public. “It’s a bit disappointing,” he said. “Currently we have to invent that part of the system.”
The stay-at-home and social distancing COVID-19 mitigation orders drastically restricted people’s physical movements and access to businesses, causing myriad secondary impacts on the public’s health. Dr. Andrea Gielen discusses how the pandemic has affected injury risks due to changes in lifestyles and transportation. Dr. Christina Mair and BCHS PhD student Jessica Frankebeger share Allegheny County results from a survey addressing resident’s ro...
WBHM - This proof-of concept study suggests that the strategy of blocking virus with antibodies holds promise. Inmaculada “Inma” Hernandez (HPM ’16), Pitt School of Pharmacy, is hopeful, but she doubts that these drugs will be a game-changer. “These drugs are so complex to produce, probably we will not have antibodies available for treating everybody who gets coronavirus. They’re probably going to be considerably expensive.”
TRIBUNE-DEMOCRAT – “We are concerned that policymakers may have interpreted the one-year downturn in 2018 as evidence for an especially effective national response or the start of a long-term trend,” said lead author Hawre Jalal, HPM. “Unfortunately, that isn’t supported by the data.” The data suggests there has been a 5.6 percent increase in fatal overdoses nationwide since 2018.
PITTSBURGH POST-GAZETTE - "We had a pretty good early run," said HPM Chair Mark Roberts, director of the Public Health Dynamics Lab. "If you look at the graph of cases over time, back in April, we were doing pretty well with surprisingly few cases." The peak day of the early months of COVID-19 came with 73 new cases on April 3 - a number that would be considered an average day today.
CUMBERLAND TIMES-NEWS - IDM’s John Mellors, UPMC’s chief of infectious diseases, said the biological molecule “is small, which means it penetrates into areas of the body where a full-sized antibody may not. It’s fully human, meaning that there’s no foreign material that’s likely to be rejected by the host… and it appears to be safe.” But he added, it's too early to talk about pricing of a treatment when it’s not (tested) in humans yet.
WASHINGTON POST – HPM's Tina Batra Hershey agrees that there's a need for executive administrations to “provide clear and transparent communications about what they’re doing, to ensure that there is a tailored response.” That might mean articulating what steps will be taken to measure whether restrictions are working and when they can be lifted, she said. “I think the judiciary will require more from the executive.”
What we have learned during the summer of 2020 that puts SARS-CoV-2 into perspective with other emerging viruses and explores the current state of COVID-19 forecasting for the next few months. IDM's Amy Hartman talks what we know (and don't know) about SARS-CoV-2 and EPI's Donald Burke discusses the epidemiological and environmental factors that will shape the likely phases of the epidemic in our region.
Teaching during this pandemic is hard. BCHS faculty and student co-authors—MPH student Shannon Mitchell (BCHS '21) and doctoral student Abisola Olaniyan (BCHS '21)—offer educators guidance on using harm-reduction principles to guide interactions with students while building compassionate, collectivist communities that allow people to learn and thrive. Check out the full article in the current edition of the journal Pedagogy in Health Promotion. ...
PITTWIRE - The Coalition for Excellence in Maternal and Child Health Epidemiology and 15 national health organizations selected EPI's Dara Mendez as the recipient of the 2020 Award for Effective Practice at the Community Level. Mendez specializes in understanding and addressing racial and socioeconomic inequity in pregnancy, birth, and women's health. The award recognizes her significant work toward improving public health practice through effec...
HPM's Mark Roberts has been appointed to the rank of Distinguished Professor at the University of Pittsburgh. Professor Roberts is Chair, Department of Health Policy and Management and Director of the Public Health Dynamics Laboratory (PHDL). In addition to his academic appointments, Dr. Roberts has held many administrative appointments, such as Director of the Institute of Clinical Research Education (ICRE) from 2007 to 2010, Senior Medical Dir...
NPR – Pitt Medical Center’s Derek Angus (BCHS ’92) said that while some worried that steroids could also prevent the body from fighting off the coronavirus, all the coordinated studies reached the same conclusion, which is, I guess we have to stop our trials. It is reassuring that we can get randomized trials executed successfully and rapidly in the face of a pandemic, and it definitely puts us on a sure footing.
LOS ANGELES TIMES – A comprehensive study from Iceland revealed that natural antibodies remained stable for four months, longer than was first thought. HPM’s Derek Angus (BCHS ’92), UPMC’s critical care chief, said that “will be encouraging for people working on vaccines.” He added that the infection fatality rate of 0.3 percent is in keeping with recent estimates here in the U.S.
TIME - EPI's Lisa Bodnar said her children's schools will begin the year all-remote. While spring “was not a good learning experience,” she feels encouraged by efforts to add more structure to the digital school day this fall. “I’m much more hopeful that it will be closer to what it could be in school. I know that they will be safer,” but she's not fully convinced that all of their needs will be met.
POLITICO - The feedback: “Not only do voluntary discounts not last long, but discounts do nothing to address the prices of drugs that come out after any discount goes into place,” tweeted HPM’s Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh. “Also, what is a 10 percent discount when list prices increases by 9.9 percent a year?”
During the COVID-19 pandemic, how have you stayed connected and maintained community connections? BCHS' Jessie Burke and Sara Baumann asked the Pitt community to respond with art projects, which are now available for viewing in a new virtual gallery featured on Pitt Public Health's website. "[A]rt space interventions like this project can be powerful approaches for reducing adverse physiological and psychological health outcomes," said Baumann. ...
NEW YORK TIMES – Many experts were bewildered about where a key statistic came from. HPM's Walid Gellad, who leads Pitt’s Center for Pharmaceutical Policy and Prescribing, said, “For the first time ever, I feel like official people in communications and people at the F.D.A. grossly misrepresented data about a therapy.” Millions will rely on the FDA' judgement. “That’s a problem if they’re starting to exaggerate data.”
PITTWIRE - From swimming devices to rare disease gene therapies, Pitt inventors never stop: The Innovation Institute reported a record 394 invention disclosures for last fiscal year, and Director Evan Facher (HUGEN '97) says another robust year is ahead.